Keratinocyte Transcriptome Changes Across Skin Microenvironments

Abstract

Keratinocytes, the predominant cell type in the epidermis, play a central role in maintaining skin homeostasis and responding to environmental cues. Recent transcriptomic analyses have revealed that keratinocytes exhibit remarkable gene expression plasticity across different skin microenvironments. These variations underlie region-specific skin functions, susceptibility to diseases, and responses to therapy. This review synthesizes current evidence on keratinocyte transcriptome dynamics, emphasizing the implications for clinical practice, risk stratification, and therapeutic innovation.

Introduction

The skin acts as a complex, multifunctional barrier, with keratinocytes forming its frontline defense and regulatory interface. Advances in single-cell RNA sequencing and spatial transcriptomics have elucidated the heterogeneous transcriptomic landscapes of keratinocytes residing in various anatomical sites and disease states. Understanding these molecular adaptations is essential for appreciating skin physiology, pathogenesis of dermatological conditions, and the development of targeted interventions.

Epidemiology / Disease Burden

Skin diseases linked to keratinocyte dysfunction, such as psoriasis, atopic dermatitis, and squamous cell carcinoma, represent substantial global health burdens. The prevalence and clinical presentations of these conditions often vary according to anatomical location, implicating microenvironment-driven transcriptomic differences. For instance, acral, scalp, and intertriginous regions exhibit unique susceptibilities and disease phenotypes, which are increasingly appreciated as consequences of site-specific keratinocyte transcriptome profiles.

Pathophysiology

Keratinocyte transcriptome alterations reflect adaptations to the diverse physical, chemical, and microbiological challenges encountered across skin microenvironments. Site-specific gene expression patterns are shaped by local gradients of cytokines, growth factors, mechanical stress, and microbiota. For example, palmoplantar keratinocytes upregulate genes associated with mechanical resilience, whereas those in sebaceous-rich areas express lipid metabolism pathways. In inflammatory diseases, aberrant transcriptomic signatures such as overexpression of IL-17/IL-23 axis genes in psoriatic plaques drive pathogenic cascades and tissue remodeling.

Risk Factors

Intrinsic factors like anatomical site, age, and genetic background, as well as extrinsic influences such as UV exposure, allergens, and microbial colonization, modulate keratinocyte transcriptomes. Chronic irritation, atopic predisposition, and immunosuppression can tip transcriptomic balances toward pro-inflammatory or dysregulated states, thereby increasing the risk for specific dermatoses or malignancies. Environmental exposures have been shown to induce stable epigenetic and transcriptional changes in keratinocytes, contributing to site-specific disease risk.

Clinical Features

Clinical manifestations of skin diseases often mirror the underlying transcriptomic landscape. For instance, lichenified plaques on extensor surfaces, intertrigo in flexures, and seborrheic dermatitis in oily regions correspond to microenvironment-driven keratinocyte gene expression. These differences influence not only morphological features but also pruritus, scaling, and barrier function. Recognizing these patterns aids in differential diagnosis and risk stratification.

Diagnosis

Emerging diagnostic techniques leverage transcriptomic profiling of keratinocytes to distinguish between disease subtypes and predict therapeutic response. Noninvasive sampling combined with RNA sequencing allows for site-specific molecular diagnosis, potentially surpassing traditional histopathology in sensitivity and specificity. Biomarkers identified in regionally distinct keratinocyte transcriptomes are under investigation for their utility in early detection and monitoring of skin diseases.

Treatment & Management

Therapeutic strategies increasingly account for microenvironmental influences on keratinocyte biology. Topical agents are formulated to target the unique lipid and protein composition of site-specific keratinocytes, while systemic therapies modulate dysregulated transcriptomic pathways (e.g., IL-17 inhibitors in psoriasis). Personalized approaches, informed by transcriptomic data, hold promise for optimizing efficacy and minimizing adverse effects, especially in recalcitrant or anatomically challenging lesions.

Recent Advances / Emerging Therapies

Recent advances include the application of spatial transcriptomics to map keratinocyte heterogeneity with unprecedented resolution, revealing novel pathogenic mechanisms and therapeutic targets. Epigenetic modifiers, RNA-based therapeutics, and microbiome-directed interventions are under investigation for their capacity to reset aberrant keratinocyte transcriptomes. Early-phase clinical trials employing small interfering RNAs or antisense oligonucleotides targeting disease-driving genes demonstrate the translational potential of transcriptome-informed therapies.

Guideline Recommendations

Leading dermatological guidelines increasingly recognize the role of site-specific biology in disease management. Recommendations emphasize the importance of tailoring treatment regimens to anatomical location, disease subtype, and individual patient factors. Incorporation of molecular diagnostics and transcriptomic biomarkers into clinical algorithms is encouraged to enhance diagnostic precision and therapeutic outcomes. Ongoing guideline updates continue to integrate findings from transcriptomic research to refine evidence-based care pathways.

Conclusion

Keratinocyte transcriptome changes across skin microenvironments underpin the diversity of skin function and disease. Advances in transcriptomic technologies are reshaping our understanding of skin biology, paving the way for precision dermatology. Clinicians and researchers should remain abreast of these developments to harness their full potential in diagnosis, risk assessment, and individualized therapy.